Featured Press Releases

Pilatus Biosciences Inc. earns FDA Orphan Drug Designation for PLT012, targeting liver and intrahepatic bile duct cancer

Pilatus Biosciences Inc. earns FDA Orphan Drug Designation for PLT012, targeting liver and intrahepatic bile duct cancer

Starting January 2026, Samsung Bioepis will commercialize BYOOVIZ® (ranibizumab) in Europe

Starting January 2026, Samsung Bioepis will commercialize BYOOVIZ® (ranibizumab) in Europe

  • 30 Oct 2025

Samsung Bioepis Co., Ltd. announced that the company has entered into an Asset Purchase Agreement...

PANTHERx® Rare is selected by Calliditas Therapeutics as the specialty pharmacy for TARPEYO®.

PANTHERx® Rare is selected by Calliditas Therapeutics as the specialty pharmacy for TARPEYO®.

Health Canada has granted Celltrion approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg).

Health Canada has granted Celltrion approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg).

OrthoTrophix reports new findings on TPX-100, revealing a structural relationship between femoral bone shape and meniscal pathology in knee osteoarthritis

OrthoTrophix reports new findings on TPX-100, revealing a structural relationship between femoral bone shape and meniscal pathology in knee osteoarthritis

Kerri McCullough Wood Named Chief Commercial Officer at Avid Bioservices

Kerri McCullough Wood Named Chief Commercial Officer at Avid Bioservices

Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34

Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34

  • Aspera Biomedicines Inc.
  • 18 May 2026
Galvanize Therapeutics receives FDA clearance for the Aliya EX Generator, expanding its Aliya Pulsed Electric Field portfolio

Galvanize Therapeutics receives FDA clearance for the Aliya EX Generator, expanding its Aliya Pulsed Electric Field portfolio

  • Galvanize Therapeutics, Inc.
  • 18 May 2026
Peter Menziuso named EVP and President of BD Interventional

Peter Menziuso named EVP and President of BD Interventional

  • BD
  • 18 May 2026
A new real-world case series examines re-induction with ADSTILADRIN in clinical practice

A new real-world case series examines re-induction with ADSTILADRIN in clinical practice

  • Ferring Pharmaceuticals
  • 17 May 2026
Biohack skin longevity with Futurecode Booster

Biohack skin longevity with Futurecode Booster

  • Dermalogica
  • 16 May 2026
ENHERTU received U.S. approval for two new indications in HER2-positive early breast cancer.

ENHERTU received U.S. approval for two new indications in HER2-positive early breast cancer.

  • AstraZeneca
  • 15 May 2026
The Digital Pharma Advances Conference 2026

Most Popular
May   2026
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.